会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Quinazoline derivatives
    • 喹唑啉衍生物
    • US09273013B2
    • 2016-03-01
    • US13744878
    • 2013-01-18
    • Janssen Pharmaceutica N.V.
    • Eddy Jean Edgard FreyneTimothy Pietro Suren PereraPeter Jacobus Johannes Antonius BuijnstersMarc WillemsGaston Stanislas Marcella DielsWerner Constant Johan EmbrechtsPeter Ten HolteFrederik Jan Rita RomboutsCarsten Schultz-Fademrecht
    • C07D239/02C07D239/94C07D239/88C07D239/93C07C229/16C07C229/40
    • C07D498/06C07C229/16C07C229/40C07D239/88C07D239/93C07D239/94
    • The present invention concerns the compounds of formula wherein Z represents NH; Y represents —C3-9alkyl-, —C2-9alkenyl-, —C3-7alkyl-CO—NH optionally substituted with amino, mono- or di(C1-4alkyl)amino or C1-4alkyloxycarbonylamino-, —C3-7alkenyl-CO—NH— optionally substituted with amino, mono- or di(C1-4alkyl)amino- or C1-4alkyloxycarbonylamino-, C1-5alkyl-NR13—C1-5alkyl-, —C1-5alkyl-NR14—CO—C1-5alkyl-, —C1-6alkyl-CO—NH—, —C1-5alkyl-CO NR15—C1-5alkyl-, —C1-3alkyl-NH—CO-Het20-, —C1-2alkyl-CO-Het21-CO—, —C1-2alkyl-NH—CO—CR16R17—NH—, —C1-2alkyl-CO—NH—CR18R19—CO—, —C1-2alkyl-CO—NR20—C1-3alkyl-CO—, or —NR22—CO—C1-3alkyl-NH—; X1 represents a direct bond, O or —O—C1-2alkyl-; X2 represents a direct bond, —CO—C1-2alkyl-, NR12, —NR12—C1-2alkyl, —O—N═CH— or —C1-2alkyl-; R1 and R2 are hydrogen or halo; R3 are hydrogen; R4 represents hydrogen or C1-4alkyloxy; R12 and R13 are hydrogen or C1-4alkyl; R14 and R15 are hydrogen; R16 and R17 each independently represent hydrogen or C1-4alkyl; R18 and R19 are hydrogen or C1-4alkyl optionally substituted with phenyl or hydroxy; R20 and R21 are hydrogen or C1-4alkyl optionally substituted with C1-4alkyloxy; Het20, Het21 and Het22 are a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy.
    • 本发明涉及下式的化合物其中Z代表NH; Y代表任选被氨基,一或二(C 1-4烷基)氨基或C 1-4烷氧基羰基氨基 - , - C 3-7烯基-CO-的氨基取代的-C 3-9烷基 - , - C 2-9烯基 - , - 氨基,一或二(C 1-4烷基)氨基 - 或C 1-4烷氧基羰基氨基 - ,C 1-5烷基-NR 13 -C 1-5烷基 - , - C 1-5烷基-NR 14 -CO-C 1-5烷基 - C 1-6烷基-CO-NH - , - C 1-5烷基-CO NR 15 -C 1-5烷基 - , - C 1-3烷基-NH-CO-Het 20 - , - C 1-2烷基-CO-Het 21 -CO-, - C 1-2烷基 -NH-CO-CR16R17-NH-,-C1-2烷基-CO-NH-CR18R19-CO-,-C1-2烷基-CO-NR20-C1-3烷基-CO-或-NR22-CO-C1-3烷基 - NH-; X1表示直接键,O或-O-C 1-2烷基 - ; X 2表示直接键,-CO-C 1-2烷基 - ,NR 12,-NR 12 -C 1-2烷基,-O-N = CH-或-C 1-2烷基 - ; R1和R2是氢或卤素; R3是氢; R4代表氢或C1-4烷氧基; R 12和R 13是氢或C 1-4烷基; R14和R15是氢; R 16和R 17各自独立地表示氢或C 1-4烷基; R 18和R 19是氢或任选被苯基或羟基取代的C 1-4烷基; R 20和R 21是氢或任选被C 1-4烷氧基取代的C 1-4烷基; Het20,Het21和Het22是选自吡咯烷基,2-吡咯烷基或任选被羟基取代的哌啶基的杂环。
    • 10. 发明授权
    • Macrocyclic quinazoline derivatives as antiproliferative agents
    • 大环喹唑啉衍生物作为抗增殖剂
    • US07648975B2
    • 2010-01-19
    • US10558007
    • 2004-05-25
    • Eddy Jean Edgard FreyneTimothy Pietro Suren PereraPeter Jacobus Johannes Antonius BuijnstersMarc WillemsGaston Stanislas Marcella DielsWerner Constant Johan Embrechts
    • Eddy Jean Edgard FreyneTimothy Pietro Suren PereraPeter Jacobus Johannes Antonius BuijnstersMarc WillemsGaston Stanislas Marcella DielsWerner Constant Johan Embrechts
    • A01N43/00A61K31/33C07D487/00C07D491/00C07D513/00
    • C07D498/06C07C229/16C07C229/40C07D239/88C07D239/93C07D239/94
    • The present invention concerns the compounds of formula (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents O, CH2, NH or S; in particular Z represents NH; Y represents —C3-9alkyl-, —C3-9alkenyl-, —C3-9alkynyl-, —C3-7alkyl-CO—NH— optionally substituted with amino, mono- or di(C1-4alkyl)amino or C1-4 alkyloxycarbonylamino-, —C3-7alkenyl-CO—NH— optionally substituted with amino, mono- or di(C1-4alkyl)amino- or C1-4alkyloxycarbonylamino-, C1-5alkyl-oxy-C1-5alkyl-, —C1-5alkyl NR13—, —C1-5alkyl-, —C1-5alkyl-NR14—CO—C1-5alkyl-, —C1-5alkyl-CO NR15—C1-5alkyl-, —C1-6alkyl-CO—NH—, —C1-6alkyl-NH—CO—, —C1-3alkyl-NH—CS-Het20-, —C1-3alkyl-NH—CO-Het20, —C1-2alkyl-CO-Het21-CO—, -Het22-CH2—CO—NH—C1-3alkyl-, —CO—NH—C1-6alkyl-, —NH—CO—C1-6alkyl-, —CO—C1-7alkyl-, —C1-7alkyl-CO—, —C1-6alkyl-CO—C1-6alkyl-, —C1-2alkyl-NH—CO—CR16R17—NH—, —C1-2alkyl-CO—NH—CR18R19—CO—, —C1-2alkyl-CO—NR20—C1-3alkyl-CO—, C1-2alkyl-NR21—CH2—CO—NH—C1-3alkyl-, or NR22—CO—C1-3alkyl-NH—, X1 represents a direct bond, O or —O—C1-2alkyl-, CO, —CO—C1-2alkyl-, NR11, —NR11—C1-2alkyl-, —CH2—, —O—N═CH— or —C1-2alkyl-; X2 represents a direct bond, O, —O—C1-2alkyl-, CO, —CO—C1-2alkyl-, NR12, —NR12—C1-2alkyl-, —CH2—, —O—N═CH— or —C1-2alkyl-. The growth inhibitory effect anti-tumour activity of the present compounds has been demonstrated in vitro, in enzymatic on the receptor tyrosine kinase EGFR.
    • 本发明涉及式(I)化合物的N-氧化物形式,其药学上可接受的加成盐和立体化学异构形式,其中Z代表O,CH2,NH或S; 特别是Z表示NH; 一个或多个(C 1-4烷基)氨基或C 1-4烷氧基羰基氨基 - 取代的C 1-3烷基 - , - C 3-9烯基 - , - C 3-9炔基 - , - 一个或多个(C 1-4烷基)氨基 - 或C 1-4烷氧基羰基氨基 - ,C 1-5烷基 - 氧基-C 1-5烷基 - , - C 1-5烷基NR 13 - , - -C1-5烷基 - , - C 1-5烷基-NR 14 -CO-C 1-5烷基 - , - C 1-5烷基-CO NR 15 -C 1-5烷基 - , - C 1-6烷基-CO-NH-,-C 1-6烷基-NH- CO-,-C 1-3烷基-NH-CS-Het20-,-C1-3烷基-NH-CO-Het20,-C1-2烷基-CO-Het21-CO-,-Het22-CH2-CO-NH-C1-3烷基 - ,-CO-NH-C 1-6烷基 - , - NH-CO-C 1-6烷基 - , - CO-C 1-7烷基 - , - C 1-7烷基-CO-,-C 1-6烷基-CO-C 1-6烷基 - -C1-2烷基-NH-CO-CR16R17-NH-,-C1-2烷基-CO-NH-CR18R19-CO-,-C1-2烷基-CO-NR20-C1-3烷基-CO-,C1-2烷基-NR21- CH2-CO-NH-C1-3烷基 - 或NR22-CO-C1-3烷基-NH-,X1表示直接键,O或-O-C 1-2烷基 - ,CO,-CO-C 1-2烷基 - ,NR 11 ,-NR 11 -C 1-2烷基 - , - CH 2 - ,--ON-CH-或-C 1-2烷基 - ; X2表示直接键合,O,-O-C 1-2烷基 - ,CO,-CO-C 1-2烷基 - ,NR 12,-NR 12 -C 1-2烷基 - , - CH 2 - ,--ON-CH-或-C 1-2烷基 - 。 本发明化合物的生长抑制作用的抗肿瘤活性已在体外证明在酶对受体酪氨酸激酶EGFR的作用。